Strand Life Sciences, a Reliance Industries subsidiary, launches CancerSpot, a groundbreaking blood-based test for early detection of multiple cancers. Using cutting-edge methylation profiling technology, the test identifies tumor DNA fragments from a simple blood sample, enabling proactive cancer screening like never before.
Speaking at the inauguration of Genomics Diagnostics & Research Centre in Bengaluru, Dr. Ramesh Hariharan, CEO and Co-Founder of Strand Life Sciences said, "Early warning is the key to battle cancer and win it. We are proud to launch an accessible early cancer detection test that will enable people to stay ahead of cancer. Over our 24-year history, Strand has been a pioneer in genomics, and this is another FIRST for India resulting from a rigorous multi- year research study”
The test’s unique design leverages Indian genomic data, ensuring global applicability and offers a convenient option for routine screening. The newly unveiled 33,000-square-foot research facility will spearhead innovations in genomics while supporting life-saving diagnostics for Indian and global populations.
Isha Ambani Piramal, Member of the Board at Reliance Industries, remarked, “Reliance is committed to reshaping the future of medicine. Strand’s novel cancer early detection test exemplifies our vision to deliver transformative healthcare solutions for India and the world.”
The facility, inaugurated by genomics pioneer Dr. Charles Cantor, houses cutting-edge sequencing technologies, fostering collaboration among leading bioinformatics experts and clinicians. Reliance Industries continues to harness genomics to advance healthcare, reducing the burden of cancer in India and beyond.
